ResMed, which we know for their sleep tracking technology, announced a definitive agreement to acquire privately held Brightree, maker of the clinical software applications for the post-acute care industry. The deal will cost ResMed $800 million, and will be funded primarily with debt.

“This acquisition furthers ResMed’s position as the leading tech-driven medical device company and gives our customers new tools to help them increase operational efficiency and improve cash-flow while delivering best-in-class patient care,” Mick Farrell, CEO of ResMed, said in a statement.

Brightree has developed a cloud-based software that helps customers improve clinical and business performance in the post-acute care industries of home/durable medical equipment (HME/DME), home health, and hospice.

Brightree will be managed independently with headquarters in Atlanta, and will get to keep its brand.Even as part of ResMed, the company will be managed independently with headquarters in Atlanta, and will get to keep its brand. For the time being, its employees, including Brightree President and CEO Dave Cormack, will continue to work in their current roles. Brightree had net sales of approximately $113 million and EBITDA of about $43 million in calendar year 2015.

The transaction is expected to close by the end of the fourth quarter of fiscal year 2016, subject to customary closing conditions and regulatory approvals.

DLA Piper is serving as ResMed’s legal counsel. William Blair & Company is serving as exclusive financial advisor to Brightree, and Cooley LLP is serving as its legal counsel.